公开(公告)号：US20180037585A1

公开(公告)日：2018-02-08

申请号：US15625604

申请日：2017-06-16

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Michele L.R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D487/04 ,  C07D498/04 ,  C07D491/22 ,  C07D491/20 ,  C07D491/147 ,  C07D487/18 ,  C07D487/14 ,  C07D471/20 ,  C07D471/14 ,  C07D487/10 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/10 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

公开(公告)号：US09856238B2

公开(公告)日：2018-01-02

申请号：US15041852

申请日：2016-02-11

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07D413/04

CPC classification number: C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D493/04

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US09708331B2

公开(公告)日：2017-07-18

申请号：US15013741

申请日：2016-02-02

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D487/14 ,  C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04 ,  C07D487/10

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/10 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

公开(公告)号：US20190055204A1

公开(公告)日：2019-02-21

申请号：US16107385

申请日：2018-08-21

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Larry Wendell Hardy ,  Michele L.R. Heffernan ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D239/88 ,  C07D487/20 ,  C07D471/20 ,  C07D491/20 ,  C07D413/04 ,  C07D471/04 ,  C07D471/14 ,  C07D487/08 ,  C07D498/04 ,  C07D417/06 ,  C07D487/04 ,  C07D401/14 ,  C07D405/06 ,  C07D403/06

Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

公开(公告)号：US20150072974A1

公开(公告)日：2015-03-12

申请号：US14399334

申请日：2013-05-09

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Phillip G. Jones ,  Robert Lew ,  Kerry L. Spear ,  Linghong Xie

IPC: C07D513/04 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/519 ,  C07D401/14 ,  A61K31/437 ,  C07D471/04 ,  C07D401/12 ,  A61K31/4709 ,  A61K45/06 ,  A61K31/551 ,  A61K31/4375

CPC classification number: C07D513/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06 ,  C07D215/26 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

Abstract translation: 本文提供了杂芳基化合物，其合成方法，包含该化合物的药物组合物及其用途。 在一个实施方案中，本文提供的化合物可用于治疗，预防和/或治疗各种疾病，例如CNS障碍和神经障碍，包括但不限于例如精神病，精神分裂症，抑郁症，运动障碍， 和帕金森病。

公开(公告)号：US10336732B2

公开(公告)日：2019-07-02

申请号：US15819372

申请日：2017-11-21

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D413/04 ,  C07D493/04 ,  C07D405/14 ,  C07D413/14

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US20190031685A1

公开(公告)日：2019-01-31

申请号：US15947343

申请日：2018-04-06

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Philip G. Jones ,  Robert Lew ,  Kerry L. Spear ,  Linghong Xie

IPC: C07D513/04 ,  A61K31/4985 ,  C07D401/04 ,  A61K31/437 ,  C07D401/12 ,  A61K31/444 ,  A61K31/4375 ,  C07D495/04 ,  A61K31/519 ,  A61K31/4709 ,  C07D231/56 ,  A61K31/496 ,  C07D215/26 ,  C07D471/04 ,  A61K45/06 ,  A61K31/551 ,  C07D401/14 ,  C07D519/00

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

公开(公告)号：US09951088B2

公开(公告)日：2018-04-24

申请号：US14399334

申请日：2013-05-09

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Philip G. Jones ,  Robert Lew ,  Kerry L. Spear ,  Linghong Xie

IPC: A61K31/506 ,  C07D513/04 ,  C07D471/04 ,  C07D401/14 ,  C07D215/26 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D495/04 ,  C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06 ,  A61K31/444

CPC classification number: C07D513/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06 ,  C07D215/26 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

公开(公告)号：US09884844B2

公开(公告)日：2018-02-06

申请号：US14758681

申请日：2013-12-31

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Qun Kevin Fang ,  Una Campbell ,  Kerry L. Spear

IPC: C07D401/04 ,  C07D491/113 ,  G01N33/50 ,  C07D401/14 ,  C07D413/14 ,  C07D487/10 ,  C07D498/10

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D487/10 ,  C07D491/113 ,  C07D498/10 ,  G01N33/5038

Abstract: Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20170001987A1

公开(公告)日：2017-01-05

申请号：US15041852

申请日：2016-02-11

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07D413/04

CPC classification number: C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D493/04

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract translation: 其中A，R a，R 1，R 2，R 3，R 4，R 6，w和n 1在本文中定义和描述; 组合物; 及其使用方法。 这些化合物可用于治疗各种神经和精神疾病，例如本文所述的那些。